Aricept (donepezil hydrochloride) from Pfizer/Eisais was the world best-selling drug till 2010, which lost patent protection in November 2010 and at present, Namenda (memantine hydrochloride) from Forest Laboratories, Exelon (rivastigmine) from Novartis and Ebixa
(memantine) from Lundbeck Ltd.
The reductions include for instance a drop in the price of Zithromax antibiotic by over 50 per cent, cholesterol pills Lipitor and Zocor by around 30 per cent, medication for nervous system disorders -- Keppra and Ebixa
-- by around 40 per cent, and musculoskeletal drugs such as Fosamax by 16 per cent.
The Hefei Zhongkeda Biological and Technology Company provided both the trial drug (domestic memantine hydrochloride tablets, 10 mg/ tablet, batch number 0810001), and the imported proprietary form of the drug (memantine hydrochloride tablets, Ebixa
, 10 mg/tablet, batch number 7088461).
NICE's current guidance to medical practitioners on the prescription of Aricept, Reminyl, Excelon and Ebixa
widens the use of these drugs to include more stages of Alzheimer's Disease.
I get up, pop my pills," he says, referring to Aricept and Ebixa
which can, in some cases, temporarily arrest the progress of Alzheimer's.
Sales of Alzheimer's drug Ebixa
saw its sales drop by 6% to DKK 667 million, which was expected due to price reductions.
Memantine, also known as Ebixa
, was originally designed for Alzheimer's and has been approved for use in NHS patients who fail to respond to other treatments.
Lundbeck's product pipeline includes therapies such as Cipralex/Lexapro, for depression; Ebixa
, for Alzheimer's disease; Azilect, for Parkinson's disease; Sabril, for epilepsy; and Sycrest, for bipolar disorder.
263) IHS GLOBAL INSIGHT, NICE Recommends Alzheimer's Drugs Aricept, Reminyl, Exelon, and Ebixa
Following Review (2010), http://www.
The revenue hike was due to a rise in sales of the key products Cipralex, Ebixa
and Azilect of 2%, 16% and 12% respectively, according to Lundbeck.
NICE further recommends that Ebixa
(memantine) now be made available to patients with moderate to severe Alzheimer's disease.
The guidance, which is subject to appeal, also recommends the use of Ebixa
(memantine) for severe disease and for some patients with moderate disease.